Literature DB >> 25865979

Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China.

W Chang, Xiaoling Ma1, P Gao, X Lv, H Lu, F Chen.   

Abstract

PURPOSE: To assess whether vancomycin minimum inhibitory concentration (MIC) creeps among clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in a regional hospital in China. Furthermore, to analyze the causes of vancomycin MIC creeps and the relationship between vancomycin MICs and the outcome among patients with MRSA infection.
MATERIALS AND METHODS: All clinical isolates of MRSA from 2006-2010 were retrieved and tested by the broth microdilution procedure to determine their vancomycin MIC. Meanwhile, related patient records were analyzed.
RESULTS: While all isolates were susceptive to vancomycin, the percentage of isolates with a vancomycin MIC = 1 mg/L increased significantly from 2006 (37.0%) to 2010 (75.7%). Meanwhile, vancomycin usage density (DDDs/1000 bed-days) had increased significantly from 2006-2010. Mean linear correlation analysis showed a statistically significant positive correlation (r = 0.905, P < 0.05) between the consumption of vancomycin and the percentage of MRSA isolates with a vancomycin MIC = 1 mg/L. Clinical records revealed high vancomycin MIC was associated with a higher microbiologic failure rate in MRSA bloodstream infections.
CONCLUSIONS: The data demonstrated vancomycin MIC creep among clinical isolates in our hospital, and the MIC creep may be caused by the increasing usage of vancomycin. Furthermore, the analysis strongly suggested this shift of vancomycin MIC within the susceptible range may be associated with an increasing probability of treatment failure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25865979     DOI: 10.4103/0255-0857.148837

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  17 in total

1.  An Unusual Occurrence of Methicillin Resistant Staphylococcal Endocarditis with Vancomycin Creep Phenomenon - A Therapeutic Challenge.

Authors:  S Sneha; Shanthan Venishetty; Shubha Seshadri; M Sudhakar Rao; Chiranjay Mukhopadhyay
Journal:  J Clin Diagn Res       Date:  2016-12-01

2.  Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Dynamic Pharmacokinetic/Pharmacodynamic Model.

Authors:  Junchen Huang; Siwei Guo; Xin Li; Fang Yuan; You Li; Bing Xu; Junyuan Gu; Yong Qiao
Journal:  Antimicrob Agents Chemother       Date:  2021-12-13       Impact factor: 5.938

3.  The use of vancomycin in the treatment of adult patients with methicillin-resistant Staphylococcus aureus (MRSA) infection: a survey in a tertiary hospital in China.

Authors:  Jing Tang; Jiali Hu; Lei Kang; Zhengjun Deng; Jiaofen Wu; Jiaqian Pan
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Decreased Vancomycin MICs among Methicillin-Resistant Staphylococcus aureus Clinical Isolates at a Chinese Tertiary Hospital over a 12-year Period.

Authors:  Chaohui Lu; Yinjuan Guo; Shanshan Wang; Zhengzheng Wang; Lan Chen; Jinnan Lv; Xiuqin Qi; Zengqiang Chen; Lizhong Han; Xueqing Zhang; Liangxing Wang; Fangyou Yu
Journal:  Front Microbiol       Date:  2016-10-27       Impact factor: 5.640

5.  A 5-year Survey Reveals Increased Susceptibility to Glycopeptides for Methicillin-Resistant Staphylococcus aureus Isolates from Staphylococcus aureus Bacteremia Patients in a Chinese Burn Center.

Authors:  Bei Jiang; Supeng Yin; Bo You; Guangtao Huang; Zichen Yang; Yulong Zhang; Yu Chen; Jing Chen; Zhiqiang Yuan; Xiancai Rao; Xiaomei Hu; Yali Gong; Yizhi Peng
Journal:  Front Microbiol       Date:  2017-12-14       Impact factor: 5.640

6.  Drug concentrations in the serum and cerebrospinal fluid of patients treated with norvancomycin after craniotomy.

Authors:  Y Wu; J Kang; Q Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-13       Impact factor: 3.267

7.  Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced In vitro Antibacterial Activity.

Authors:  Hung-Jen Tang; Chih-Cheng Lai; Chi-Chung Chen; Chun-Cheng Zhang; Tzu-Chieh Weng; Wen-Liang Yu; Hung-Jui Chen; Yu-Hsin Chiu; Wen-Chien Ko; Yin-Ching Chuang
Journal:  Front Microbiol       Date:  2017-05-18       Impact factor: 5.640

8.  Lessons Learned from an Experience with Vancomycin-Intermediate Staphylococcus aureus Outbreak in a Newly Built Secondary Hospital in Korea.

Authors:  Min Hyung Kim; Yong Chan Kim; Heejung Kim; Hyuk Min Lee; Ju Hyun Lee; Da Ae Kim; Chanhee Kim; Jin Young Park; Yoon Soo Park
Journal:  Pathogens       Date:  2021-05-06

9.  Systematic review and meta-analysis of the epidemiology of vancomycin-resistance Staphylococcus aureus isolates.

Authors:  Qianxing Wu; Niloofar Sabokroo; Yujie Wang; Marzieh Hashemian; Somayeh Karamollahi; Ebrahim Kouhsari
Journal:  Antimicrob Resist Infect Control       Date:  2021-06-30       Impact factor: 4.887

Review 10.  Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.

Authors:  Shanshan Zhang; Xiaoxi Sun; Wenjiao Chang; Yuanyuan Dai; Xiaoling Ma
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.